Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (20272)	12/17/2004 10:22:48 AM
From: Suma	Read Replies (3) \| Respond to of 78571

Mrk had the same problem with VIOX and yet it has recovered nicely. Don't you think PFE might do the same ? I am a holder..

To: Spekulatius who wrote (20272)	12/17/2004 4:18:55 PM
From: Bob Rudd	Respond to of 78571

PFE - OUCH I'm holding. Unless Celebrex is pulled, lawsuits will not be a big deal...nothing like Vioxx, IMO. Less than 1% of patients are on a dosage as high as the 400mg...at the bottom end of the range where problems were seen. There have been many other studies that did not show any CV risk for Celebrex; some even showed protective properties. Merrill estimated a worst case EPS hit of .12 [05 from 2.26 to 2.14] based on a revenue drop from 3.9B to 2.5B [-36%]...that implies a PE of 12 at 25.85. Just about any drug you pick up has numerous warnings and risks. Alternative non-specific NSAID's for Arthritis pain relief are considered to have greater risk of ulcers. For Dr's and patients it's a matter of weighing risks since there's no risk-free options. Frankly, I'd add if I didn't already have what I consider a full position[too full it turns out]. But then my judgement when it comes to drug stocks has been consistently flawed.